A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo - Wikidata - awgldk - TriplyDB

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

http://www.wikidata.org/entity/Q34491149

about

Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal Notch Signaling in Neuroendocrine Tumors Small cell lung cancer (SCLC): no treatment advances in recent years Cellular and molecular biology of small cell lung cancer: an overview Targeting angiogenesis in small cell lung cancer ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering Selective gene expression analysis of the neuroepithelial body microenvironment in postnatal lungs with special interest for potential stem cell characteristics.Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).Research progress in the treatment of small cell lung cancer.Role of tumor microenvironment in tumorigenesis.What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.Synthesis, DNA binding affinity and anticancer activity of novel 4H-benzo[g][1,2,3]triazolo[5,1-c][1,4]oxazocines.Unravelling the biology of SCLC: implications for therapy.Ganetespib for small cell lung cancer.Prospects and progress of antibody-drug conjugates in solid tumor therapies.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Strategies and challenges for the next generation of antibody-drug conjugates.Emerging Variants of Castration-Resistant Prostate Cancer.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.Update in Lung Cancer 2015.Targeting the seeds of small cell lung cancer Emerging strategies for the treatment of advanced small cell lung cancer.ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.Major milestones in translational oncology.Unraveling the genomic complexity of small cell lung cancer.Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse.Relevance of genetic alterations in squamous and small cell lung cancer.Venetoclax is effective in small cell lung cancers with high BCL-2 expression.Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates.Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.

P2860

Q26744536-6F11B632-AD33-4EC4-8139-34A2E96768B2 Q26752380-C6BE8F9E-7AAD-47CC-8B2E-675F63532AB7 Q26767020-25C75C6E-E949-49D5-9EEA-DC528FAFE437 Q26767029-29CBC30B-971C-4B99-B130-436AAEA548A3 Q28068385-93A70E9E-5752-4A04-9A74-2ABB01E3E73A Q28602015-1892F0AC-8CCA-42C9-9B90-7F986748C9D2 Q28828981-4954128A-5C82-4A78-B459-0E3F8CC6078C Q30238552-8F04C131-4195-4512-B441-F647694F4DF1 Q33437481-E4F66F29-A77D-4AA4-975E-D78CE7C2C73A Q33587970-FF480B4A-8E9B-4EC0-A81E-CA63724799D3 Q33651475-04A74B70-071D-467F-A6B4-B54B9F1FA6BF Q36270042-4E5F98F3-C51B-48CB-AE7A-F6C09E2F9D0B Q36811784-E2CE96C8-AE16-4BAC-A21B-53F0BC15717F Q37561359-2CC5B989-8847-43F6-AE0B-4C90DF37E156 Q37604301-77A0654B-44F5-4780-AC57-9027D2E6E56B Q37738074-75596B78-6AEF-477A-A4F1-DAA6D0B24BDA Q38661479-194419F2-096A-42A4-AB38-46F8718D9685 Q38742130-1BE8CB31-EDC7-4F43-937C-BCD996698AE0 Q38769421-EA9BAE81-780E-44D2-8F98-6F23BFDF95B3 Q38786678-0182B063-FE3A-4714-992E-29F0CCB98153 Q38798525-684B1CF7-DFAF-4145-A510-BB08AA8D7CC5 Q39019412-8BA2D6D0-D96A-40BC-8BD4-9234937976CC Q39182945-927800B8-5C53-4574-93BB-99B0649BE369 Q39210257-2CE865C1-AF54-4A87-AAFB-EBE08309E643 Q39210427-30405D29-3106-4352-835A-D1BBF8CA9043 Q39393217-BD45624C-A9A2-4464-A94A-2577154489C5 Q40208474-77263CFB-7592-47D3-900E-7C378E95FCD8 Q41115829-47F4C6E1-ED83-4F31-AC57-FDEADA2AEA92 Q42314900-19450C3F-40A2-48CE-B827-60949289D258 Q42369314-909A1B73-C0E3-447E-AB95-8C47A478B2D7 Q42382121-F9BAAE4A-C131-4A9B-AA1D-695285AC7A96 Q42398020-7D990BD7-E804-4D51-B0A3-96FF3B333F34 Q42398708-1F21EA67-F0CC-45BB-ACC6-29DE7CC573D7 Q42408728-645FF59F-A7E9-4A67-BAF7-88106AEC62F6 Q42623025-A472AC31-9E5D-4C21-BDD7-AE6E09F2AE46 Q44483486-719D9BAE-CE4C-44F0-A411-AE7BC0C76D9C Q45072361-1ECC93DC-0807-4D94-9D85-939824CE0804 Q46352637-591A7882-E3BC-4B27-A4CC-1276038B53C2 Q47120183-2C9A5E95-3C63-4982-BBA9-4879E31C00E3 Q47139670-67B08318-3901-4709-B652-6D2B04A07AF0

P2860

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

http://www.wikidata.org/entity/Q34491149

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@ast

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@en

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@nl

type

label

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@ast

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@en

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@nl

prefLabel

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@ast

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@en

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@nl

P1433

Q34491149-F985B237-801E-47A8-983C-275F97250199

P1476

Q34491149-E7F658DD-DD01-4D1F-9ECB-1E65ABE4303F

P2093

Q34491149-0ECD8E9E-E2CF-4284-BE2E-49615EE9C07E

Q34491149-0F9C5E37-8AEF-45CD-B5EC-8BBDE4E1E3E3

Q34491149-10C492CB-479A-4733-896B-D45B130F542E

Q34491149-129B7497-452A-4AB3-9166-0B1FEDD75BAA

Q34491149-1F8D05AB-12F3-4045-ADAA-F03654601FFF

Q34491149-2D3732D6-D264-4A0A-8210-02B7E560212F

Q34491149-35582560-050B-4E55-871F-EC351798E4D8

Q34491149-44D553EC-E242-442F-AE2F-0308823E730D

Q34491149-45513BAD-E880-487D-87AD-EAB26347C941

Q34491149-462CFDAD-BD19-4D64-9E54-F46071C14509

P2860

Q34491149-02D8C47A-EB01-48BE-B6B5-BD912E11123C

Q34491149-03F4FE39-3CA5-452F-8959-8E107928A0A0

Q34491149-0A79F8B3-568D-4DA5-8BE7-C29CC07D29ED

Q34491149-1254B7E8-748B-4E6C-8886-18ECFDEF7B54

Q34491149-1815B3B2-035A-4104-B93C-5A206C013F4F

Q34491149-183A4930-E07F-4963-95A7-0720642DC4C3

Q34491149-29327746-BA23-4818-9E97-59E473E6AEAE

Q34491149-2F6D3B3E-9B9E-4CFC-80F7-FB8296CC848A

Q34491149-32D6207C-4425-4AB5-80B7-E711A3F7BA06

Q34491149-3354317C-B863-40CC-B66F-709FA77A97FE

P304

Q34491149-100CBEF6-2F26-415C-96C7-465B836D79AF

P31

Q34491149-29D498AA-B9B6-4D0A-BD95-EF316C1154D4

P356

Q34491149-CE20332B-29BB-4D6C-B0E6-74B006C310FB

P407

Q34491149-365B66C1-FF2C-4B73-A9A7-8161EF8ADB69

P433

Q34491149-3949ABFC-7339-410E-B24B-8A0AB02453CE

P478

Q34491149-90D8E12D-6146-4FC4-B9C4-22F5EA793089

P50

Q34491149-3ADD5D45-A6FF-4431-B1A4-382A731A759E

Q34491149-660B50C4-858B-4007-AA06-BDD5DEFF5FA1

Q34491149-C9AF06BB-1376-41C9-BB9A-EB40964ADF4D

Q34491149-FD36F966-86EE-4A37-8090-085C99D2D804

P577

Q34491149-E94A6B3D-CB11-490B-8303-1C043B0CF965

P698

Q34491149-71BB40D9-22DD-4640-A8E1-0228E443E111

P921

Q34491149-D939D897-9F69-4C85-B8D7-CE4AA8E46845

P932

Q34491149-089523AA-7801-4322-8476-401D0BB8E7A2

P356

SCITRANSLMED.AAC9459

P1433

Science Translational Medicine

P1476

A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo

@en

P2093

Afshin Dowlati

http://www.w3.org/2001/XMLSchema#string

Albert Park

http://www.w3.org/2001/XMLSchema#string

Amy Laysang

http://www.w3.org/2001/XMLSchema#string

Andrzej Badzio

http://www.w3.org/2001/XMLSchema#string

Brian Slingerland

http://www.w3.org/2001/XMLSchema#string

David H Harpole

http://www.w3.org/2001/XMLSchema#string

David Liu

http://www.w3.org/2001/XMLSchema#string

Hui Shao

http://www.w3.org/2001/XMLSchema#string

J T Poirier

http://www.w3.org/2001/XMLSchema#string

Javier Lopez-Molina

http://www.w3.org/2001/XMLSchema#string

P2860

The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136

From fly wings to targeted cancer therapies: a centennial for notch signaling

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

An achaete-scute homologue essential for neuroendocrine differentiation in the lung

Lineage dependency and lineage-survival oncogenes in human cancer

On the origin and destination of cancer stem cells: a conceptual evaluation

O-fucosylation of DLL3 is required for its function during somitogenesis

The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands

Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium

Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo

P304

302ra136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAC9459

http://www.w3.org/2001/XMLSchema#string

P407

P433

302

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J. Bankovich

Samuel A Williams

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26311731

http://www.w3.org/2001/XMLSchema#string

P921

P932

4934375

http://www.w3.org/2001/XMLSchema#string